secwatch.observer — SEC 8-K summary
======================================

Issuer:     INTEGRA LIFESCIENCES HOLDINGS CORP (IART)
CIK:        0000917520
Form:       8-K
Filed at:   2025-02-25T23:59:59+00:00
Accession:  0000917520-25-000014
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Integra LifeSciences Q4 adj EPS $0.97 (+9% YoY); FY24 GAAP EPS ($0.09); 2025 adj EPS guidance $2.41-$2.51
--------------------------------------------------------------------------------

- Q4 2024: rev $442.6M (+11.5% rep, +3.5% org); adj EPS $0.97 vs $0.89; GAAP EPS $0.25 flat YoY.
- FY2024: rev $1,610.5M (+4.5% rep, -1.3% org); GAAP EPS ($0.09) vs $0.84; adj EPS $2.56 vs $3.10.
- FY2025 guidance: rev $1,650M-$1,715M (+2.4-6.5% rep, +1.0-5.0% org); adj EPS $2.41-$2.51 (below 2024 adj EPS $2.56).
- Q1 2025 guidance: rev $375M-$385M (+1.6-4.4% rep); org rev -6.2% to -3.5% due to ship holds & Integra Skin delays.
- Net debt $1.5B; leverage ratio 4.0x; FY2024 cash from ops $129.4M, capex $104.0M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/917520/000091752025000014/0000917520-25-000014-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/917520/000091752025000014/iart-20250225.htm
  HTML page:      https://secwatch.observer/filing/0000917520-25-000014

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer